Axmed vs CytoReason
Axmed vs CytoReason, compared side by side on 12 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Axmed is on 40/100 and CytoReason on 68/100.
Where each one leads
Axmed
Leads on none of the measures we hold for both companies.
CytoReason
- our overall score: 68/100 against 40/100
- funding raised: $128M against $5.0M
At a glance
| Measure | Axmed | CytoReason |
|---|---|---|
| What it is | Distributing affordable medicines. | Develops a computational model of the human body for drug discovery and development. |
| Category | Healthcare, Logistics, Pharmaceuticals | Healthcare, Drug Discovery, Clinical Development, Biomarkers |
| Sells toBusiness model | B2B | B2B |
| Offering | Services | Software |
| Founded | Not published | 2016 |
| Headquarters | Basel, Switzerland | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | Axmed | CytoReason |
|---|---|---|
| Employees | Not published | 116 |
| Headcount growthLast 12 months | Not published | +13.7% |
| Total funding | $5.0M | $128M |
| Latest round | Unknown | Series B |
| LinkedIn followers | Not published | 12,830 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Axmed | CytoReason |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 40/100 | 68/100 |
| Traction | 33/100 | 60/100 |
| Team | Not published | 70/100 |
| Search visibility | 12/100 | 30/100 |
| Quality | 58/100 | 78/100 |
| Agent readinessHow well an AI agent can read and act on the site | Not published | F (21/100) |
| Domain ratingLink authority, 0-100 | Not published | 40/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Axmed | CytoReason |
|---|---|---|
| Analytics | Not detected | Segment |
Axmed vs CytoReason: common questions
Which is better, Axmed or CytoReason?
On our 0-100 score CytoReason rates higher (68/100 against 40/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 12 data points above: read the rows that match what you are buying for.
How do Axmed and CytoReason compare on the numbers?
CytoReason leads on our overall score (68/100 against 40/100), funding raised ($128M against $5.0M).
Read the full Axmed review and pricing or the CytoReason review and pricing. You can also browse other Axmed alternatives we track.